share_log

Angion Biomedica analyst ratings

Angion Biomedica analyst ratings

Angion Biomedica 分析師評級
Benzinga Analyst Ratings ·  2022/07/18 18:14
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/18/2022 HC Wainwright & Co. Downgrades Buy → Neutral
06/30/2022 Oppenheimer Downgrades Outperform → Perform
06/30/2022 41.51% Stifel $5 → $1.5 Downgrades Buy → Hold
05/23/2022 2541.51% HC Wainwright & Co. $32 → $28 Maintains Buy
04/18/2022 2918.87% HC Wainwright & Co. $50 → $32 Maintains Buy
12/10/2021 654.72% Oppenheimer $15 → $8 Maintains Outperform
11/09/2021 4616.98% HC Wainwright & Co. $100 → $50 Maintains Buy
10/27/2021 1315.09% Stifel $40 → $15 Maintains Buy
03/02/2021 Cowen & Co. Initiates Coverage On → Outperform
03/02/2021 3484.91% Oppenheimer → $38 Initiates Coverage On → Outperform
03/02/2021 3673.58% Stifel → $40 Initiates Coverage On → Buy
03/01/2021 9333.96% HC Wainwright & Co. → $100 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
07/18/2022 - HC Wainwright公司 評級下調 購買→中性
2022/06/30 - 奧本海默 評級下調 超越→表現
2022/06/30 41.51% Stifel $5→$1.5 評級下調 購買→Hold
2022年05月23日 2541.51% HC Wainwright公司 $32→$28 維護
04/18/2022 2918.87% HC Wainwright公司 $50→$32 維護
2021年12月10日 654.72% 奧本海默 $15→$8 維護 跑贏大盤
11/09/2021 4616.98% HC Wainwright公司 $100→$50 維護
10/27/2021 1315.09% Stifel $40→$15 維護
03/02/2021 - 考恩公司 開始承保 →跑贏大盤
03/02/2021 3484.91% 奧本海默 →$38 開始承保 →跑贏大盤
03/02/2021 3673.58% Stifel →$40 開始承保 →購買
03/01/2021 9333.96% HC Wainwright公司 →$100 開始承保 →購買

Angion Biomedica Questions & Answers

Angion Biomedica問答

What is the target price for Angion Biomedica (ANGN)?
Angion Biomedica(ANGN)的目標價是多少?

The latest price target for Angion Biomedica (NASDAQ: ANGN) was reported by HC Wainwright & Co. on July 18, 2022. The analyst firm set a price target for $0.00 expecting ANGN to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.

納斯達克(Angion Biomedica)的最新目標價是由HC Wainwright&Co.於2022年7月18日報道的。這家分析公司將目標價定為0.00美元,預計ANGN將在12個月內下跌(跌幅可能為-100.00%)。去年有8家分析公司公佈了評級。

What is the most recent analyst rating for Angion Biomedica (ANGN)?
Angion Biomedica(ANGN)的最新分析師評級是多少?

The latest analyst rating for Angion Biomedica (NASDAQ: ANGN) was provided by HC Wainwright & Co., and Angion Biomedica downgraded their neutral rating.

納斯達克的最新分析師評級是由HC Wainwright&Co.提供的,Angion Biomedica下調了其中性評級。

When is the next analyst rating going to be posted or updated for Angion Biomedica (ANGN)?
Angion Biomedica(ANGN)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Angion Biomedica, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Angion Biomedica was filed on July 18, 2022 so you should expect the next rating to be made available sometime around July 18, 2023.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與Angion Biomedica的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Angion Biomedica的上一次評級是在2022年7月18日提交的,所以你應該預計下一次評級將在2023年7月18日左右的某個時候提供。

Is the Analyst Rating Angion Biomedica (ANGN) correct?
分析師對Angion Biomedica(ANGN)的評級正確嗎?

While ratings are subjective and will change, the latest Angion Biomedica (ANGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Angion Biomedica (ANGN) is trading at is $1.06, which is out of the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的Angion Biomedica(ANGN)評級被下調,目標價為0.00美元至0.00美元。Angion Biomedica(ANGN)目前的股價為1.06美元,超出了分析師的預測區間。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論